Comparative distribution of somatostatin and somatostatin receptors in PTU-induced hypothyroidism.
Hypothyroidism
Immunohistochemistry
Propylthiouracil
Somatostatin and somatostatin receptors
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
22
01
2020
accepted:
06
04
2020
pubmed:
27
4
2020
medline:
28
5
2021
entrez:
27
4
2020
Statut:
ppublish
Résumé
Propylthiouracil (PTU)-induced hypothyroidism is a well-established model for assessing hormonal and morphological changes in thyroid as well as other central and peripheral tissues. Somatostatin (SST) is known to regulate hormonal secretion and synthesis in endocrine tissues; however, nothing is currently known about the distribution of SST and its receptor in hypothyroidism. In the present study, the comparative immunohistochemical distribution of SST and somatostatin receptors (SSTRs) were analyzed in PTU-induced hypothyroid rats. Rats were treated with PTU for 15 days followed by a co-administration of levothyroxine (LVT) for 15 days. After PTU and LVT treatments (day 30), rats were further administered LVT alone for 15 more days (day 45). The subcellular distribution of SST and SSTR subtypes was determined by peroxidase immunohistochemistry in the thyroid gland collected from control and treated rats. SST and SSTR subtypes were found to be moderately expressed in control thyroid tissues. SST and SSTR subtypes like immunoreactivity increased significantly in follicular and parafollicular epithelial cells in the thyroid of PTU-treated rats. The PTU-induced changes in the expression of SST and SSTR subtypes were suppressed by the administration of the LVT. In addition to thyroid tissues, SST and SSTRs expression was also changed in non-follicular tissues including blood vessels, smooth muscle cells, and connective tissue following treatments. The present study revealed a distinct subcellular distribution of SST and SSTR subtypes in the thyroid and provides a new insight for the role of SST and SSTR subtypes in hypothyroidism in addition to its well-established role in negative regulation of hormonal secretion.
Identifiants
pubmed: 32335798
doi: 10.1007/s12020-020-02309-1
pii: 10.1007/s12020-020-02309-1
doi:
Substances chimiques
Receptors, Somatostatin
0
Somatostatin
51110-01-1
Propylthiouracil
721M9407IY
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
92-106Subventions
Organisme : CIHR
ID : MOP 74465
Pays : Canada
Organisme : Natural Sciences and Engineering Research Council
ID : 402594-11
Pays : International
Organisme : CIHR
ID : MOP 74465
Pays : Canada
Organisme : CIHR
ID : MOP 74465
Pays : Canada
Références
B.B. Mughal, J.B. Fini, B.A. Demeneix, Thyroid-disrupting chemicals and brain development: an update. Endocr. Connect. 7(4), R160–R186 (2018). https://doi.org/10.1530/EC-18-0029
doi: 10.1530/EC-18-0029
pubmed: 29572405
pmcid: 5890081
C. Chen, Z. Xie, Y. Shen, S.F. Xia, The roles of thyroid and thyroid hormone in pancreas: physiology and pathology. Int. J. Endocrinol. 2018, 2861034 (2018). https://doi.org/10.1155/2018/2861034
doi: 10.1155/2018/2861034
pubmed: 30013597
pmcid: 6022313
O. Tarim, Thyroid hormones and growth in health and disease. J. Clin. Res. Pediatr. Endocrinol. 3(2), 51–55 (2011). https://doi.org/10.4274/jcrpe.v3i2.11
doi: 10.4274/jcrpe.v3i2.11
pubmed: 21750631
pmcid: 3119440
M.P. Vanderpump, The epidemiology of thyroid disease. Br. Med. Bull. 99, 39–51 (2011). https://doi.org/10.1093/bmb/ldr030
doi: 10.1093/bmb/ldr030
pubmed: 21893493
H. Katakami, T.R. Downs, L.A. Frohman, Decreased hypothalamic growth hormone-releasing hormone content and pituitary responsiveness in hypothyroidism. J. Clin. Investig. 77(5), 1704–1711 (1986). https://doi.org/10.1172/JCI112490
doi: 10.1172/JCI112490
pubmed: 2871046
M. Sato, J. Takahara, Y. Fujioka, M. Niimi, S. Irino, Physiological role of growth hormone (GH)-releasing factor and somatostatin in the dynamics of GH secretion in adult male rat. Endocrinology 123(4), 1928–1933 (1988). https://doi.org/10.1210/endo-123-4-1928
doi: 10.1210/endo-123-4-1928
pubmed: 2901340
Y.C. Patel, Somatostatin and its receptor family. Front. Neuroendocrinol. 20(3), 157–198 (1999). https://doi.org/10.1006/frne.1999.0183
doi: 10.1006/frne.1999.0183
pubmed: 10433861
P. Brazeau, W. Vale, R. Burgus, N. Ling, M. Butcher, J. Rivier, R. Guillemin, Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179(4068), 77–79 (1973). https://doi.org/10.1126/science.179.4068.77
doi: 10.1126/science.179.4068.77
pubmed: 4682131
U. Kumar, R. Sasi, S. Suresh, A. Patel, M. Thangaraju, P. Metrakos, S.C. Patel, Y.C. Patel, Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. Diabetes 48(1), 77–85 (1999). https://doi.org/10.2337/diabetes.48.1.77
doi: 10.2337/diabetes.48.1.77
pubmed: 9892225
C. Bruns, G. Weckbecker, F. Raulf, K. Kaupmann, P. Schoeffter, D. Hoyer, H. Lubbert, Molecular pharmacology of somatostatin-receptor subtypes. Ann. N. Y. Acad. Sci. 733, 138–146 (1994). https://doi.org/10.1111/j.1749-6632.1994.tb17263.x
doi: 10.1111/j.1749-6632.1994.tb17263.x
pubmed: 7978861
R. Danesi, C. Agen, U. Benelli, A.D. Paolo, D. Nardini, G. Bocci, F. Basolo, A. Campagni, M.D. Tacca, Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995). Clin. Cancer Res. 3(2), 265–272 (1997)
pubmed: 9815682
U. Kumar, M. Grant, Somatostatin and somatostatin receptors. Results Probl. Cell Differ. 50, 137–184 (2010). https://doi.org/10.1007/400_2009_29
doi: 10.1007/400_2009_29
pubmed: 19859675
A. Schonbrunn, H. Tashjian Jr, Characterization of functional receptors for somatostatin in rat pituitary cells in culture. J. Biol. Chem. 253(18), 6473–6483 (1978)
pubmed: 210185
M. Vanetti, M. Kouba, X. Wang, G. Vogt, V. Hollt, Cloning and expression of a novel mouse somatostatin receptor (SSTR2B). FEBS Lett. 311(3), 290–294 (1992). https://doi.org/10.1016/0014-5793(92)81122-3
doi: 10.1016/0014-5793(92)81122-3
pubmed: 1397330
K. Sharma, Y.C. Patel, C.B. Srikant, Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol. Endocrinol. 10(12), 1688–1696 (1996). https://doi.org/10.1210/mend.10.12.8961277
doi: 10.1210/mend.10.12.8961277
pubmed: 8961277
Z. Helyes, E. Pinter, K. Sandor, K. Elekes, A. Banvolgyi, D. Keszthelyi, E. Szoke, D.M. Toth, Z. Sandor, L. Kereskai, G. Pozsgai, J.P. Allen, P.C. Emson, A. Markovics, J. Szolcsanyi, Impaired defense mechanism against inflammation, hyperalgesia, and airway hyperreactivity in somatostatin 4 receptor gene-deleted mice. Proc. Natl Acad. Sci. USA 106(31), 13088–13093 (2009). https://doi.org/10.1073/pnas.0900681106
doi: 10.1073/pnas.0900681106
pubmed: 19622729
J.L. Ramirez, M. Grant, M. Norman, X.P. Wang, S. Moldovan, F.J. de Mayo, C. Brunicardi, U. Kumar, Deficiency of somatostatin (SST) receptor type 5 (SSTR5) is associated with sexually dimorphic changes in the expression of SST and SST receptors in brain and pancreas. Mol. Cell. Endocrinol. 221(1-2), 105–119 (2004). https://doi.org/10.1016/j.mce.2004.02.001
doi: 10.1016/j.mce.2004.02.001
pubmed: 15223137
U. Kumar, Colocalization of somatostatin receptor subtypes (SSTR1-5) with somatostatin, NADPH-diaphorase (NADPH-d), and tyrosine hydroxylase in the rat hypothalamus. J. Comp. Neurol. 504(2), 185–205 (2007). https://doi.org/10.1002/cne.21444
doi: 10.1002/cne.21444
pubmed: 17626271
U. Kumar, S.I. Grigorakis, H.L. Watt, R. Sasi, L. Snell, P. Watson, S. Chaudhari, Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1-5 and correlation with receptor protein expression and tumor pathology. Breast Cancer Res. Treat. 92(2), 175–186 (2005). https://doi.org/10.1007/s10549-005-2414-0
doi: 10.1007/s10549-005-2414-0
pubmed: 15986128
U. Kumar, D. Laird, C.B. Srikant, E. Escher, Y.C. Patel, Expression of the five somatostatin receptor (SSTR1-5) subtypes in rat pituitary somatotrophes: quantitative analysis by double-layer immunofluorescence confocal microscopy. Endocrinology 138(10), 4473–4476 (1997). https://doi.org/10.1210/endo.138.10.5566
doi: 10.1210/endo.138.10.5566
pubmed: 9322965
S. Panda, A. Khar, Possible amelioration of hyperthyroidism by the leaf extract of Annona squamosa. Curr. Sci. 84, 1402–1404 (2003)
F. Varghese, A.B. Bukhari, R. Malhotra, A. De, IHC Profiler: an open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples. PloS ONE. 9(5), e96801 (2014). https://doi.org/10.1371/journal.pone.0096801
doi: 10.1371/journal.pone.0096801
pubmed: 24802416
pmcid: 4011881
E. Cano-Europa, V. Blas-Valdivia, M. Franco-Colin, C.A. Gallardo-Casas, R. Ortiz-Butron, Methimazole-induced hypothyroidism causes cellular damage in the spleen, heart, liver, lung and kidney. Acta. Histochem. 113(1), 1–5 (2011). https://doi.org/10.1016/j.acthis.2009.07.004
doi: 10.1016/j.acthis.2009.07.004
pubmed: 19775732
M. Mohibbullah, K.M.I. Bashir, S.K. Kim, Y.K. Hong, A. Kim, S.K. Ku, J.S. Choi. Protective effects of a mixed plant extracts derived from Astragalus membranaceus and Laminaria japonica on PTU-induced hypothyroidism and liver damages. J. Food Biochem. 43(7), e12853 (2019). https://doi.org/10.1111/jfbc.12853
J.H. Hwang, H.W. Jung, S.Y. Kang, A.N. Kang, J.N. Ma, X.L. Meng, M.S. Hwang, Y.K. Park, Therapeutic effects of acupuncture with MOK, a polyherbal medicine, on PTU-induced hypothyroidism in rats. Exp. Ther. Med 16(1), 310–320 (2018). https://doi.org/10.3892/etm.2018.6190
doi: 10.3892/etm.2018.6190
pubmed: 29896255
pmcid: 5995081
F. Asiaei, A. Fazel, A.A. Rajabzadeh, M. Hosseini, F. Beheshti, M. Seghatoleslam, Neuroprotective effects of Nigella sativa extract upon the hippocampus in PTU-induced hypothyroidism juvenile rats: a stereological study. Metab. Brain Dis. 32(5), 1755–1765 (2017). https://doi.org/10.1007/s11011-017-0025-1
doi: 10.1007/s11011-017-0025-1
pubmed: 28497360
S. Bhanja, G.B.N. Chainy, PTU-induced hypothyroidism modulates antioxidant defence status in the developing cerebellum. Int J. Dev. Neurosci. 28(3), 251–262 (2010). https://doi.org/10.1016/j.ijdevneu.2010.01.005
doi: 10.1016/j.ijdevneu.2010.01.005
pubmed: 20123122
R. Wilen, C.H. Bastomsky, F. Naftolin, Control of puberty in female rats—the effect of Ptu-Induced hypothyroidism and systematic undernutrition. Pediatr. Res 15(2), 169–171 (1981). https://doi.org/10.1203/00006450-198102000-00019
doi: 10.1203/00006450-198102000-00019
pubmed: 7254943
C. Lucke, B. Hoffken, A. von zur Muhlen, The effect of somatostatin on TSH levels in patients with primary hypothyroidism. J. Clin. Endocrinol. Metab. 41(06), 1082–1084 (1975). https://doi.org/10.1210/jcem-41-6-1082
doi: 10.1210/jcem-41-6-1082
pubmed: 1206095
S.W. Lamberts, J. Zuyderwijk, F. den Holder, P. van Koetsveld, L. Hofland, Studies on the conditions determining the inhibitory effect of somatostatin on adrenocorticotropin, prolactin and thyrotropin release by cultured rat pituitary cells. Neuroendocrinology 50(1), 44–50 (1989). https://doi.org/10.1159/000125200
doi: 10.1159/000125200
pubmed: 2569172
J. Weeke, A.P. Hansen, K. Lundaek, Inhibition by somatostatin of basal levels of serum thyrotropin (TSH) in normal men. J. Clin. Endocrinol. Metab. 41(1), 168–171 (1975). https://doi.org/10.1210/jcem-41-1-168
doi: 10.1210/jcem-41-1-168
pubmed: 1171113
S. Mariotti, P. Beck-Peccoz. Physiology of the hypothalamic-pituitary-thyroid axis. In: K.R. Feingold, B. Anawalt, A. Boyce, G. Chrousos, K. Dungan, A. Grossman, J.M. Hershman, G. Kaltsas, C. Koch, P. Kopp, M. Korbonits, R. McLachlan, J.E. Morley, M. New, L. Perreault, J. Purnell, R. Rebar, F. Singer, D.L. Trence, A. Vinik, D.P. Wilson. (eds.) Endotext. South Dartmouth (MA) (2000)
A. Arimura, A.V. Schally, Increase in basal and thyrotropin-releasing hormone (TRH)-stimulated secretion of thyrotropin (TSH) by passive immunization with antiserum to somatostatin in rats. Endocrinology 98(4), 1069–1072 (1976). https://doi.org/10.1210/endo-98-4-1069
doi: 10.1210/endo-98-4-1069
pubmed: 819248
I. Yang, J. Woo, S. Kim, J. Kim, Y. Kim, Y. Choi, Suppression of TRH-stimulated TSH secretion by glucose-induced hypothalamic somatostatin release. Horm. Metab. Res. 28(10), 553–557 (1996). https://doi.org/10.1055/s-2007-979851
doi: 10.1055/s-2007-979851
pubmed: 8934215
M. Berelowitz, K. Maeda, S. Harris, L.A. Frohman, The effect of alterations in the pituitary-thyroid axis on hypothalamic content and in vitro release of somatostatin-like immunoreactivity. Endocrinology 107(1), 24–29 (1980). https://doi.org/10.1210/endo-107-1-24
doi: 10.1210/endo-107-1-24
pubmed: 6103803
S. Skare, K.F. Hanssen, N. Norman, Plasma somatostatin is elevated in primary hypothyroidism compared with hyperthyroidism. Acta Endocrinol. Cop. 111(3), 331–335 (1986). https://doi.org/10.1530/acta.0.1110331
doi: 10.1530/acta.0.1110331
K.B. Ain, K.D. Taylor, S. Tofiq, G. Venkataraman, Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines. J. Clin. Endocrinol. Metab. 82(6), 1857–1862 (1997). https://doi.org/10.1210/jcem.82.6.4013
doi: 10.1210/jcem.82.6.4013
pubmed: 9177396
D. Hoyer, G.I. Bell, M. Berelowitz, J. Epelbaum, W. Feniuk, P.P. Humphrey, A.M. O’Carroll, Y.C. Patel, A. Schonbrunn, J.E. Taylor et al. Classification and nomenclature of somatostatin receptors. Trends Pharmacol. Sci. 16(3), 86–88 (1995)
doi: 10.1016/S0165-6147(00)88988-9
C. Scarpignato, I. Pelosini, Somatostatin analogs for cancer treatment and diagnosis: an overview. Chemotherapy 47(Suppl 2), 1–29 (2001). https://doi.org/10.1159/000049157
doi: 10.1159/000049157
pubmed: 11275699
H. Pisarek, T. Stepien, R. Kubiak, E. Borkowska, M. Pawlikowski, Expression of somatostatin receptor subtypes in human thyroid tumors: the immunohistochemical and molecular biology (RT-PCR) investigation. Thyroid Res. 2(1), 1 (2009). https://doi.org/10.1186/1756-6614-2-1
doi: 10.1186/1756-6614-2-1
pubmed: 19173713
pmcid: 2646698
H. Pisarek, M. Pawlikowski, M. Marchlewska, R. Minias, K. Winczyk, An immunohistochemical investigation of the expression of somatostatin receptor subtypes - should therapeutic trials be performed to determine the efficacy of somatostatin analogs in treating advanced thyroid malignances? Exp. Clin. Endocrinol. Diabetes. 123(6), 342–346 (2015). https://doi.org/10.1055/s-0035-1548825
doi: 10.1055/s-0035-1548825
pubmed: 25962406
F. Sundler, J. Alumets, R. Hakanson, L. Bjorklund, O. Ljungberg, Somatostatin-immunoreactive cells in medullary carcinoma of the thyroid. Am. J. Pathol. 88(2), 381–386 (1977)
pubmed: 195473
pmcid: 2032172
T. Hokfelt, S. Efendic, C. Hellerstrom, O. Johansson, R. Luft, A. Arimura, Cellular localization of somatostatin in endocrine-like cells and neurons of the rat with special references to the A1-cells of the pancreatic islets and to the hypothalamus. Acta Endocrinologica. Supplementum 200, 5–41 (1975)
doi: 10.1530/acta.0.080S005
J.A. Parsons, S.L. Erlandsen, O.D. Hegre, R.C. McEvoy, R.P. Elde, Central and peripheral localization of somatostatin. Immunoenzyme immunocytochemical studies. J. Histochem. Cytochem. 24(7), 872–882 (1976). https://doi.org/10.1177/24.7.60436
doi: 10.1177/24.7.60436
pubmed: 60436
I. Shimon, J.E. Taylor, J.Z. Dong, R.A. Bitonte, S. Kim, B. Morgan, D.H. Coy, M.D. Culler, S. Melmed, Somatostatin receptor subtype specificity in human fetal pituitary cultures—differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J. Clin. Investig. 99(4), 789–798 (1997). https://doi.org/10.1172/Jci119225
doi: 10.1172/Jci119225
pubmed: 9045884
B. De Groef, K.L. Geris, J. Manzano, J. Bernal, R.P. Millar, A.B. Abou-Samra, T.E. Porter, A. Iwasawa, E.R. Kuhn, V.M. Darras, Involvement of thyrotropin-releasing hormone receptor, somatostatin receptor subtype 2 and corticotropin-releasing hormone receptor type 1 in the control of chicken thyrotropin secretion. Mol. Cell. Endocrinol. 203(1–2), 33–39 (2003). https://doi.org/10.1016/S0303-7207(03)00120-5
doi: 10.1016/S0303-7207(03)00120-5
pubmed: 12782401
M. Papotti, U. Kumar, M. Volante, C. Pecchioni, Y.C. Patel, Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid. Clin. Endocrinol. 54(5), 641–649 (2001)
doi: 10.1046/j.1365-2265.2001.01175.x
R.C. Patel, U. Kumar, D.C. Lamb, J.S. Eid, M. Rocheville, M. Grant, A. Rani, T. Hazlett, S.C. Patel, E. Gratton, Y.C. Patel, Ligand binding to somatostatin receptors induces receptor-specific oligomer formation in live cells. Proc. Natl Acad. Sci. USA 99(5), 3294–3299 (2002). https://doi.org/10.1073/pnas.042705099
doi: 10.1073/pnas.042705099
pubmed: 11880655
H. Atkinson, J.A. England, A. Rafferty, V. Jesudason, K. Bedford, L. Karsai, S.L. Atkin, Somatostatin receptor expression in thyroid disease. Int. J. Exp. Pathol. 94(3), 226–229 (2013). https://doi.org/10.1111/iep.12024
doi: 10.1111/iep.12024
pubmed: 23672766
pmcid: 3664968
Y. Taniyama, T. Suzuki, Y. Mikami, T. Moriya, S. Satomi, H. Sasano, Systemic distribution of somatostatin receptor subtypes in human: an immunohistochemical study. Endocr. J. 52(5), 605–611 (2005). https://doi.org/10.1507/endocrj.52.605
doi: 10.1507/endocrj.52.605
pubmed: 16284440
Y. Fujii, T. Gonoi, Y. Yamada, K. Chihara, N. Inagaki, S. Seino, Somatostatin receptor subtype SSTR2 mediates the inhibition of high-voltage-activated calcium channels by somatostatin and its analogue SMS 201-995. FEBS Lett. 355(2), 117–120 (1994). https://doi.org/10.1016/0014-5793(94)01159-1
doi: 10.1016/0014-5793(94)01159-1
pubmed: 7982482
A.F. Abdel-Magid, Treating pain with somatostatin receptor subtype 4 agonists. ACS Med. Chem. Lett. 6(2), 110–111 (2015). https://doi.org/10.1021/ml500538a
doi: 10.1021/ml500538a
pubmed: 25699156
pmcid: 4329573
R.K. Somvanshi, U. Kumar, delta-opioid receptor and somatostatin receptor-4 heterodimerization: possible implications in modulation of pain associated signaling. PloS ONE 9(1), e85193 (2014). https://doi.org/10.1371/journal.pone.0085193
doi: 10.1371/journal.pone.0085193
pubmed: 24416361
pmcid: 3885706
Z. Varecza, K. Elekes, T. Laszlo, A. Perkecz, E. Pinter, Z. Sandor, J. Szolcsanyi, D. Keszthelyi, A. Szabo, K. Sandor, T.F. Molnar, Z. Szanto, J.E. Pongracz, Z. Helyes. Expression of the somatostatin receptor subtype 4 in intact and inflamed pulmonary tissues. J. Histochem. Cytochem. 57(12), 1127–1137 (2009). https://doi.org/10.1369/jhc.2009.953919 .
T. Endo, T. Saito, T. Uchida, T. Onaya, Effects of somatostatin and serotonin on calcitonin secretion from cultured rat parafollicular cells. Acta Endocrinol. (Copenh) 117(2), 214–218 (1988). https://doi.org/10.1530/acta.0.1170214
doi: 10.1530/acta.0.1170214
E. Mato, X. Matias-Guiu, A. Chico, S.M. Webb, R. Cabezas, L. Berna, A. De Leiva, Somatostatin and somatostatin receptor subtype gene expression in medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 83(7), 2417–2420 (1998). https://doi.org/10.1210/jcem.83.7.4955
doi: 10.1210/jcem.83.7.4955
pubmed: 9661621
S. Reichlin, Somatostatin .1. N. Engl. J. Med 309(24), 1495–1501 (1983). https://doi.org/10.1056/Nejm198312153092406
doi: 10.1056/Nejm198312153092406
pubmed: 6139753
S. Van Noorden, J.M. Polak, A.G. Pearse, Single cellular origin of somatostatin and calcitonin in the rat thyroid gland. Histochemistry 53(3), 243–247 (1977). https://doi.org/10.1007/bf00511079
doi: 10.1007/bf00511079
pubmed: 334709
B.R. Haugen, Drugs that suppress TSH or cause central hypothyroidism. Best practice & research. Clin. Endocrinol. Metab. 23(6), 793–800 (2009). https://doi.org/10.1016/j.beem.2009.08.003
doi: 10.1016/j.beem.2009.08.003
B.M. Lewis, C. Dieguez, M.D. Lewis, M.F. Scanlon, Dopamine stimulates release of thyrotrophin-releasing hormone from perfused intact rat hypothalamus via hypothalamic D2-receptors. J. Endocrinol. 115(3), 419–424 (1987). https://doi.org/10.1677/joe.0.1150419
doi: 10.1677/joe.0.1150419
pubmed: 2965205
D. Mannavola, L. Persani, G. Vannucchi, M. Zanardelli, L. Fugazzola, U. Verga, M. Facchetti, P. Beck-Peccoz, Different responses to chronic somatostatin analogues in patients with central hyperthyroidism. Clin. Endocrinol. 62(2), 176–181 (2005). https://doi.org/10.1111/j.1365-2265.2004.02192.x
doi: 10.1111/j.1365-2265.2004.02192.x
M.H. Samuels, P. Henry, E.C. Ridgway, Effects of dopamine and somatostatin on pulsatile pituitary glycoprotein secretion. J. Clin. Endocrinol. Metab. 74(1), 217–222 (1992). https://doi.org/10.1210/jcem.74.1.1345783
doi: 10.1210/jcem.74.1.1345783
pubmed: 1345783
A. Gruszka, M.D. Culler, S. Melmed, Somatostatin analogs and chimeric somatostatin-dopamine molecules differentially regulate human growth hormone and prolactin gene expression and secretion in vitro. Mol. Cell. Endocrinol. 362(1-2), 104–109 (2012). https://doi.org/10.1016/j.mce.2012.05.020
doi: 10.1016/j.mce.2012.05.020
pubmed: 22705877
M. Boscaro, W.H. Ludlam, B. Atkinson, J.E. Glusman, S. Petersenn, M. Reincke, P. Snyder, A. Tabarin, B.M. Biller, J. Findling, S. Melmed, C.H. Darby, K. Hu, Y. Wang, P.U. Freda, A.B. Grossman, L.A. Frohman, J. Bertherat, Treatment of pituitary-dependent Cushing’s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J. Clin. Endocrinol. Metab. 94(1), 115–122 (2009). https://doi.org/10.1210/jc.2008-1008
doi: 10.1210/jc.2008-1008
pubmed: 18957506
A. Ben-Shlomo, S. Melmed, Somatostatin agonists for treatment of acromegaly. Mol. Cell. Endocrinol. 286(1–2), 192–198 (2008). https://doi.org/10.1016/j.mce.2007.11.024
doi: 10.1016/j.mce.2007.11.024
pubmed: 18191325
J. Yang, N. Yi, J. Zhang, W. He, D. He, W. Wu, S. Xu, F. Li, G. Fan, X. Zhu, Z. Xue, W. Zhou, Generation and characterization of a hypothyroidism rat model with truncated thyroid stimulating hormone receptor. Sci. Rep. 8(1), 4004 (2018). https://doi.org/10.1038/s41598-018-22405-7
doi: 10.1038/s41598-018-22405-7
pubmed: 29507327
pmcid: 5838214